Qureight’s AI-powered quantitative imaging analytics platform and services to analyse HRCT images to evaluate changes in compartment-specific lung biomarkers
The focus of these efforts will be on the quantitative assessment of change from baseline in lung fibrosis
Qureight’s imaging models, including Glass8™, Fibr8™, Vascul8™, Air8™ and Lung8™, enable precise compartment-specific assessment of inflammatory, fibrotic, vascular and airway-related changes in the lungs, supporting deeper understanding of disease progression and therapeutic response in Systemic Sclerosis
MTX-474 is a monoclonal…
Amsbio reports how researchers from the Karolinska Institute, Stockholm, Sweden are using their Adeno Associated Virus (AAV) products in a groundbreaking investigation into the causes of Rheumatoid Arthritis pain.
Rheumatoid arthritis (RA) pain is not explained well by inflammation alone. In a new peer reviewed study** the Swedish researchers describe the multitude of approaches they used to uncover the neural basis and causes of the inflammatory pain. In one described methodology the researchers used AAV produced by Amsbio for conditional Ifnar1 knockout in sensory neuron and pharmacological…
o2h Discovery, a leading integrated drug discovery CRO, today announces the launch of the latest edition of o2h Kickstarter Award for Peptide, a dedicated programme/Award designed to support early-stage biotech companies advancing peptide-based therapeutics.
Building on the success of the o2h Kickstarter Award, which has supported more than 40 early-stage biotech companies globally since 2022, o2h Discovery is now expanding its flagship initiative to address the growing demand for peptide drug discovery expertise. The Peptide Kickstarter Award is purpose-built for startups working on peptide-…
AI hallucinations in drug discovery aren't just an AI problem — they're a data problem.
👉 52% of life science professionals say poor data quality is the #1 barrier to AI implementation
👉 27% of organisations can't even trace the evidence chain powering their AI systems.
In this new white-paper authored by Digital Science's Mark Hahnel we see the practical playbook: FAIR data principles, knowledge graphs, and neuro-symbolic AI for building a foundation pharma can actually trust.
If you're navigating AI in R&D and wondering why it isn't delivering, this is for…
Rapid binder triage, of AI-driven candidate sets, enables early elimination of non-binders ahead of costly downstream workflows
Powered by cell-free technology to convert AI-generated candidates into experimental binding data
Cambridge, UK and Boston MA, USA, 11 May 2026: Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its antibody screening service to streamline the transition from antibody hit generation to lead selection. The service will support researchers seeking to identify the most promising antibody candidates to…
The Cambridge Life Sciences Careers Fair gives you the opportunity to meet all students and researchers across the university including undergraduates, MPhils, PhDs and postdocs. Attendees will be interested in learning more about the variety of roles available in the life science sector, from roles in Research & Development as well as a broad range of non-research career paths.
We welcome organisations working across therapeutics, drug discovery, and reagents in the biomedical field in addition to those focusing on plant science, agriculture and healthcare. We'll also be welcoming a wide…
The recent cyberattack on Stryker, a leading medical technology manufacturer, serves as a stark reminder of the escalating risks posed by state-linked cyber threats to commercial organisations. Attributed to the Iran-linked hacktivist group Handala, the attack caused widespread disruption across 79 countries, wiping over 200,000 devices and compromising 50 terabytes of data. The attack underscores the urgent need for robust identity governance, network segmentation, and resilient backup strategies to mitigate the impact of such attacks.
With the ongoing geopolitical tensions in the Middle…
Cambridge entrepreneur Mark Boon has launched Aguila, a new insurance broker in Cambridge, to support founders at the forefront of the exploding life science and deeptech revolutions, unlocking potential for expansion across the UK, EU and US.
Having spent the last five years focussed on the US startup scene, Mark has turned his attention back to Cambridge, together with Co-Founder Luke Chesworth, identifying an unmet need for a deeper understanding by insurance advisers on the emerging risks in this hotbed of intellectual property, AI and compute power.
As AI-driven medical innovation…
Global industry experts in pulmonary diseases appointed: Marc Humbert, Steven Nathan, Oksana Shlobin, Vincent Cottin, Ardeschir Ghofrani, Joanna Pepke-Zaba and Luke Howard
SAB will provide strategic and scientific perspectives to support development of Qureight’s AI imaging models for clinical trials in pulmonary hypertension
Cambridge, UK, 05 May 2026 – Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has established a Scientific Advisory Board (SAB)…
First Letting Secured at Sidney Sussex Building, Chesterford Research Park
Three-storey, multi-occupancy R&D building welcomes Camena Bioscience
Cambridge, UK, 28th April 2026: Chesterford Research Park has secured the first letting at the newly completed Sidney Sussex Building, with Suite 5 (2,910 sq ft) taken by existing occupier Camena Bioscience (Camena).
The move sees Camena relocate from the Park’s Science Village to consolidate its team within a single, purpose-built, fully fitted laboratory and office suite, enabling the company to benefit…